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| INTRODUCTION
Bladder carcinoma represents the first and second most common urological malignancy in China and USA, respectively. 1, 2 Radical cystectomy is the main treatment modality for muscle-invasive and high-risk nonmuscle-invasive urothelial carcinoma of the bladder. 3 Although open surgery remains the most commonly adopted surgical approach, robot-assisted radical cystectomy (RARC) has evolved over the last few years to become an acceptable option for patients with bladder cancer. With advances in da Vinci robot systems and surgical skills, three-year overall survival (OS) rates after RARC have reached 61%-80%. 4 Noteworthy, some bladder cancer patients still die within the first year from RARC. The preoperative identification of these patients has a strong clinical value, since these patients can be selected for neoadjuvant chemotherapy rather than upfront surgery. However, it is difficult to identify patients who are at high risk of early mortality due to the poor prognostic value of the traditional TNM staging system. Previous researches have identified various predictors of early mortality among patients receiving radical cystectomy, but few of them included only preoperative factors. [5] [6] [7] The objective of this study was to explore preoperative predictors associated with higher risk of early death (within 1 year after RARC) for bladder cancer patients.
| METHODS
We retrospectively reviewed 186 patients with bladder cancer who underwent RARC between October 2014 and May 2017 in our institution. No bladder cancer patients received neoadjuvant chemotherapy before RARC. The primary objective was the identification of preoperative predictors of early death, which were defined as death within 1 year of RARC. 8 The following variables were studied: patient age, gender, American Societyof Anesthesiologists (ASA) score, body mass index (BMI), no. of tumors, preoperative clinical stage, and hydronephrosis. Preoperative laboratory evaluation should include complete blood count, fibrinogen, and liver function testing. The endpoint of the study was OS, which was calculated from the day of surgery to the time of any-cause mortality, or was censored at the date of recent follow-up.
9,10 PNI was calculated as albumin level (g/L) + 5 × lymphocyte count (10 9 /L), 10 NLR as neutrophil/lymphocyte count, PLR as platelet/lymphocyte ratio, LMR as lymphocyte/monocyte count, and AGR as albumin/(total protein-albumin). 10 Receiver operating characteristic (ROC) curve analysis was used to compare the prognostic ability of each indicator for each OS event according to the area under the ROC curve (AUC) and to determine the best cutoff points. 10 Patients were classified into two categories according to the cutoff values.
Cox univariate analysis was used to identify prognostic factors for predicting 1-year OS, estimating hazard ratios (HRs), and 95% confidence intervals (CIs). Factors significant on univariate analysis were included in Cox proportional-hazards multivariate models. 10 Analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL). All tests were two-sided and a P < 0.05 was considered statistically significant. LGPUC, low-grade papillary urothelial carcinoma; LMR, lymphocyte-monocyte ratio; NLR, neutrophil-lymphocyte ratio; NUC, non-urothelial carcinoma; PLR, platelet-lymphocyte ratio; PNI, prognostic nutritional index; PUNLMP, papillary urothelial neoplasm of low malignant potential; UC, urothelial carcinoma.
| RESULTS
A total of 186 patients were included in this study. The clinicopathological characteristics of all patients are shown in (Figure 1 ).
Median follow-up time after RARC was 20.6 months (1.2-43.7 months). Fifty-one patients (27.4%) died during follow-up and 31 (16.7%) within 1 year from surgery. Table 2 compares the preoperative risk factors for postoperative death within 1 year after RARC. One-year mortality was significantly associated with age, clinical stage, fibrinogen, NLR, PLR, and PNI.
In Cox univariate analysis, six prognostic variables were associated with higher risk of early death within 1 year after RARC: older age (P = 0.004), advanced clinical stage (P = 0.005), presence of hydronephrosis (P = 0.021), higher fibrinogen (P = 0.007), higher PLR (P = 0.031) and lower PNI (P = 0.016) ( Table 3) . On multivariate Cox stepwise analysis, older age (>60 years: HR = 7.303, 95% CI 1.734-30.764; P = 0.007) (Figure 2 ) and higher fibrinogen (≥3.295 g/L: HR = 2.396, 95% CI 1.138-5.045; P = 0.007) (Figure 3 
| DISCUSSION
Our goal was to identify preoperative risk factors predicting 1-year mortality after RARC. Such early death might be caused by underestimation of tumor stage, aggressive characteristic of bladder cancer, or perioperative complications. 11 We found that older age and higher plasma fibrinogen levels were individual predictors in the multivariate models. This may guide the urologist in oncologic outcome prediction and in choosing eligible patients who might benefit from adjuvant systemic therapy.
Traditionally, prognostic factors for bladder cancer have been focusing on tumor stage and histological grade. Noteworthy, older patients have more years to compound comorbidities which may influence survival of bladder cancer patients. It is unclear whether patient age is an independent prognostic factor for patients undergoing RARC and there is still much discrepancy in previous studies. Some studies have shown that age is associated with poor survival [12] [13] [14] while others have suggested that it is not a prognostic factor in multivariate analysis. [15] [16] [17] Although experienced surgeons could safely carry out RARC in elderly patients, 17 ,18 the present findings suggested that elderly patients (>60 years) have worse OS compared with younger patients (≤60 years) undergoing RARC. Many patients with bladder cancer were found to have hydronephrosis due to ureteral orifice obstruction by tumor. Although pathologic stage is regarded as crucial prognostic characteristic after radical cystectomy, the prognostic role of hydronephrosis has been investigated with conflicting results. [19] [20] [21] [22] To the best our knowledge, the relationship between the presence of preoperative hydronephrosis and F I G U R E 1 Receiver operating characteristic (ROC) curves for overall survival | ZHU et al.
prognosis after RARC has not yet been investigated. In our study, we found that preoperative hydronephrosis was significantly associated with 1-year mortality after RARC T A B L E 2 ( Continued) according to univariate cox regression. This could assist in assessing the prognosis of patients and deciding therapeutic plans preoperatively. Increasing studies shows that an interactive relationship exists between haemostatic factors and tumor biology. 23, 24 Fibrinogen, one of the haemostatic factors, is a plasmaglyco protein whick plays a key role in clot formation and wound healing. 24 Previous studies have demonstrated that elevated pre-therapeutic plasma fibrinogen levels are associated with worse outcome in patients with ovarian or endometrial cancer. 25, 26 Tanaka et al demonstrated that preoperative plasma fibrinogen level was an independent prognostic variable for poor survival after radical nephroureterectomy in patients with upper tract urothelial carcinoma. 24 Liu and colleagues observed that elevated preoperative plasma fibrinogen level was an independent predictor of advanced clinical stage in patients with bladder cancer. 27 However, the prognostic value of plasma fibrinogen levels for bladder cancer patients receiving radical cystectomy has not yet been reported. We believe that preoperative plasma fibrinogen levels might become a useful biomarker in clinical practice. However, some limitations of the present study warrant mention. First, the study was limited by the inherent drawbacks of its retrospective design. Second, this study was a single, tertiary-care institution study. Finally, the number of patients is somewhat small to make a final conclusion on this matter. Thus, we are conducting a prospective randomized study to confirm the results in real clinical practice.
| CONCLUSIONS
In summary, age and preoperative plasma fibrinogen level are independent predictors for 1-year mortality after RARC. To the best of our knowledge, this is the first study to investigate the prognostic value of preoperative plasma fibrinogen levels in bladder cancer patients treated with RARC. We believe that preoperative plasma fibrinogen levels might become a useful biomarker for innovative systemic therapy aiming at improving prognosis in these patients.
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